AbbVie Inc. reported strong Q3 results with revenue up 10.3% year-over-year to $17.4 billion, beating analyst expectations. Non-GAAP earnings per share more than doubled, rising 105.4%. The company's IL-23 antagonist drug Skyrizi saw sales grow 22.7% year-over-year to $5.78 billion, driving growth. AbbVie also raised its full-year 2026 adjusted diluted EPS guidance, signaling confidence in continued performance. These results reinforce AbbVie's leadership in immune-mediated inflammatory diseases and support a positive outlook for investors.
AbbVie shares are trading at USD 295.19 with a 1.45% gain as of Oct 31, 2026 00:51 WIB on Pluang, reflecting strong investor interest. The stock shows a full buy order activity at Pluang, indicating confidence among retail investors. This momentum aligns with AbbVie's robust Q3 results and raised earnings guidance.
Nasdaq futures fell over 2% due to a sell-off in Big Tech stocks like Intel and Amazon, dragging the tech-heavy index down. Meanwhile, the Dow Jones Industrial Average remained flat, supported by strong earnings beats from companies like Chevron and ...
AbbVie reported a strong third quarter with adjusted diluted earnings per share (EPS) of $3.82, more than doubling from the previous year, driven by a 10.3% increase in net revenues to $17.4 billion. Key growth came from its immunology and neuroscien...
AbbVie overcame the loss of exclusivity for its blockbuster drug Humira by successfully growing sales of new drugs Skyrizi and Rinvoq, alongside strategic acquisitions like Allergan. Over the past decade, a $1,000 investment in AbbVie grew to $7,464,...
Four NYSE-listed dividend stocks—UPS, AbbVie, Chevron, and Realty Income—are highlighted for their reliable dividends supported by strong cash flow and long histories of payouts. UPS offers a high yield of about 6.24% with improving dividend coverage...
AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to g...
